VRDN Q4 2024 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72,000+0.0% YoY

Gross Profit

$72,000100.0% margin

Operating Income

-$87M-121488.9% margin

Net Income

-$80M-110729.2% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

-16.3%

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$73M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$742M

Total Liabilities

$71M

Stockholders' Equity

$672M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72,000	$72,000	+0.0%
Gross Profit	$72,000	$72,000	+0.0%
Operating Income	-$87M	-$71M	-22.4%
Net Income	-$80M	-$67M	-19.2%

Revenue Segments

Collaboration Revenue

$100,000100%